UPDATE 1-Celgene's Revlimid shines, revenue beats estimates
October 27, 2016 at 08:02 AM EDT
Oct 27 (Reuters) - U.S. biotechnology company Celgene Corp raised its profit and revenue forecast for the year and posted third-quarter results that beat Wall Street estimates, lifted by higher demand for its flagship multiple myeloma drug, Revlimid.
